Suppr超能文献

儿童重症社区获得性肺炎的抗生素治疗方案:一项随机临床研究。

Antibiotic treatment schemes for very severe community-acquired pneumonia in children: a randomized clinical study.

机构信息

Departamento de Pediatria, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista, Botucatu, SP, Brazil.

出版信息

Rev Panam Salud Publica. 2011 Jun;29(6):444-50.

Abstract

OBJECTIVE

To compare clinical response to initial empiric treatment with oxacillin plus ceftriaxone and amoxicillin plus clavulanic acid in hospitalized children diagnosed with very severe community-acquired pneumonia (CAP).

METHODS

A prospective randomized clinical study was conducted among children 2 months to 5 years old with a diagnosis of very severe CAP in the pediatric ward of São Paulo State University Hospital in Botucatu, São Paulo, Brazil, from April 2007 to May 2008. Patients were randomly divided into two groups by type of treatment: an oxacillin/ceftriaxone group (OCG, n = 48) and an amoxicillin/clavulanic acid group (ACG, n = 56). Analyzed outcomes were: time to clinical improvement (fever and tachypnea), time on oxygen therapy, length of stay in hospital, need to widen antimicrobial spectrum, and complications (including pleural effusion).

RESULTS

The two groups did not differ statistically for age, sex, symptom duration before admission, or previous antibiotic treatment. Time to improve tachypnea was less among ACG patients than OCG patients (4.8 ± 2.2 versus 5.8 ± 2.4 days respectively; P = 0.028), as was length of hospital stay (11.0 ± 6.2 versus 14.4 ± 4.5 days respectively; P = 0.002). There were no statistically significant differences between the two groups for fever improvement time, time on oxygen therapy, need to widen antimicrobial spectrum, or frequency of pleural effusion.

CONCLUSIONS

Both treatment plans are effective in treating very severe CAP in 2-month-to 5-year-old hospitalized children. The only analyzed outcome that favored amoxicillin/clavulanic acid treatment was time required to improve tachypnea.

TRIAL REGISTRATION

ClinicalTrials.gov ID: NCT01166932.

摘要

目的

比较初始经验性治疗使用苯唑西林+头孢曲松与阿莫西林+克拉维酸对住院诊断为重症社区获得性肺炎(CAP)患儿的临床疗效。

方法

本前瞻性随机临床研究纳入了巴西圣保罗州立大学博图卡图医院儿科病房 2 个月至 5 岁诊断为重症 CAP 的患儿,研究时间为 2007 年 4 月至 2008 年 5 月。根据治疗方案将患者分为两组:苯唑西林/头孢曲松组(OCG,n=48)和阿莫西林/克拉维酸组(ACG,n=56)。分析的结果包括:临床改善(发热和呼吸急促)时间、氧疗时间、住院时间、需要扩大抗菌谱以及并发症(包括胸腔积液)。

结果

两组患儿在年龄、性别、入院前症状持续时间或既往抗生素治疗方面无统计学差异。ACG 组患者呼吸急促改善时间短于 OCG 组(分别为 4.8±2.2 天和 5.8±2.4 天;P=0.028),住院时间也短于 OCG 组(分别为 11.0±6.2 天和 14.4±4.5 天;P=0.002)。两组患儿在发热改善时间、氧疗时间、需要扩大抗菌谱或胸腔积液发生率方面无统计学差异。

结论

两种治疗方案对 2 个月至 5 岁住院重症 CAP 患儿均有效。唯一有利于阿莫西林/克拉维酸治疗的分析结果是呼吸急促改善所需时间。

临床试验注册

ClinicalTrials.gov 编号:NCT01166932。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验